Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) Short Interest Down 14.0% in June

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) was the recipient of a large decrease in short interest in June. As of June 15th, there was short interest totalling 47,353,700 shares, a decrease of 14.0% from the May 31st total of 55,038,700 shares. Based on an average trading volume of 2,945,900 shares, the short-interest ratio is currently 16.1 days.

Northwest Biotherapeutics Stock Performance

Shares of Northwest Biotherapeutics stock opened at $0.43 on Friday. The stock has a 50-day moving average price of $0.46 and a 200 day moving average price of $0.55. The company has a market cap of $524.63 million, a P/E ratio of -6.10 and a beta of -0.63. Northwest Biotherapeutics has a 1 year low of $0.40 and a 1 year high of $1.09.

Northwest Biotherapeutics (OTCMKTS:NWBO) last announced its quarterly earnings data on Friday, May 10th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter. The company had revenue of $0.28 million during the quarter.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.